Citations (81)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Sumaira Yousuf, Shabnam Shabir & Mahendra P. Singh. (2023) Protection Against Drug-Induced Liver Injuries Through Nutraceuticals via Amelioration of Nrf-2 Signaling. Journal of the American Nutrition Association 42:5, pages 495-515.
Read now
Read now
S. A. Kandarakis, P. Petrou, E. Papakonstantinou, D. Spiropoulos, A. Rapanou & I. Georgalas. (2020) Ocular nonsteroidal inflammatory drugs: where do we stand today?. Cutaneous and Ocular Toxicology 39:3, pages 200-212.
Read now
Read now
Barry A Schechter. (2019) Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies. Clinical Ophthalmology 13, pages 1439-1460.
Read now
Read now
Noriaki Nagai, Fumihiko Ogata, Hiroko Otake, Yosuke Nakazawa & Naohito Kawasaki. (2019) Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles. International Journal of Nanomedicine 14, pages 1213-1227.
Read now
Read now
Scott M Wentz, Francis Price, Alon Harris, Brent Siesky & Thomas Ciulla. (2019) Efficacy and safety of bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract surgery. Expert Opinion on Pharmacotherapy 20:14, pages 1703-1709.
Read now
Read now
John D Sheppard. (2016) Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review. Clinical Ophthalmology 10, pages 2099-2111.
Read now
Read now
Kamran Hosseini, Thomas Walters, Robert DaVanzo & Richard L Lindstrom. (2016) A randomized double-masked study to compare the ocular safety, tolerability, and efficacy of bromfenac 0.075% compared with vehicle in cataract surgery subjects. Clinical Ophthalmology 10, pages 2311-2317.
Read now
Read now
George A Baklayan & Mauricio Muñoz. (2014) The ocular distribution of 14C-labeled bromfenac ophthalmic solution 0.07% in a rabbit model. Clinical Ophthalmology 8, pages 1717-1724.
Read now
Read now
Ester Carreño, Alejandro Portero, David J Galarreta & José M Herreras. (2012) Update on twice-daily bromfenac sodium sesquihydrate to treat postoperative ocular inflammation following cataract extraction. Clinical Ophthalmology 6, pages 637-644.
Read now
Read now
Rahul Reddy & Stephen Jae Kim. (2011) Critical appraisal of ophthalmic ketorolac in treatment of pain and inflammation following cataract surgery. Clinical Ophthalmology 5, pages 751-758.
Read now
Read now
Xiao Jing Wang, Sze H Wong, Roshan Givergis & Emil W Chynn. (2011) Evaluation of analgesic efficacy of bromfenac sodium ophthalmic solution 0.09% versus ketorolac tromethamine ophthalmic solution 0.5% following LASEK or Epi-LASIK. Clinical Ophthalmology 5, pages 1451-1457.
Read now
Read now
Hyung Cho, Kenneth J Wolf & Eric J Wolf. (2009) Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clinical Ophthalmology 3, pages 199-210.
Read now
Read now
Helga P Sandoval & Kerry D Solomon. (2009) Ketorolac tromethamine 0.4% to relieve eye pain and inflammation following cataract extraction and keratorefractive surgery. Expert Review of Ophthalmology 4:5, pages 461-468.
Read now
Read now
Shiro Higaki, Keizo Watanabe, Motoki Itahashi & Yoshikazu Shimomura. (2009) Cyclooxygenase (COX)-Inhibiting Drug Reduces HSV-1 Reactivation in the Mouse Eye Model. Current Eye Research 34:3, pages 171-176.
Read now
Read now
Henry D Perry & Eric D Donnenfeld. (2008) Bromfenac ophthalmic solution 0.09%: ocular role and systemic safety profile. Expert Review of Ophthalmology 3:2, pages 121-129.
Read now
Read now
Helga P Sandoval, Luis E Fernández de Castro, David T Vroman & Kerry D Solomon. (2007) A review of the use of ketorolac tromethamine 0.4% in the treatment of post-surgical inflammation following cataract and refractive surgery. Clinical Ophthalmology 1:4, pages 367-371.
Read now
Read now
Articles from other publishers (65)
Fidencio Abner Rojas-Aguilar, Alfredo Briones-Aranda, Osmar Antonio Jaramillo-Morales, Rodrigo Romero-Nava, Héctor Armando Esquinca-Avilés & Josué Vidal Espinosa-Juárez. (2023) The Additive Antinociceptive Effect of Resveratrol and Ketorolac in the Formalin Test in Mice. Pharmaceuticals 16:8, pages 1078.
Crossref
Crossref
Apipa Wanasathop, Patcharawan Nimmansophon, Michael Murawsky, Deepak G. Krishnan & S. Kevin Li. (2023) Iontophoresis on Porcine and Human Gingiva. Pharmaceutical Research.
Crossref
Crossref
Milena Sokolowska, G Enrico Rovati, Zuzana Diamant, Eva Untersmayr, Jürgen Schwarze, Zuzanna Lukasik, Florentina Sava, Alba Angelina, Oscar Palomares, Cezmi A. Akdis, Liam O'Mahony, Milos Jesenak, Oliver Pfaar, María José Torres, Marek Sanak, Sven‐Erik Dahlén & Grzegorz Woszczek. (2022) Effects of non‐steroidal anti‐inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID‐19. Allergy 77:8, pages 2337-2354.
Crossref
Crossref
Dong-Hyun Lee, Minha Kim, Eun-Young Choi, Hee-Seung Chin & Min Kim. (2022) Efficacy of Pretreatment with Preservative-Free Topical Bromfenac in Improving Post-Intravitreal-Injection Pain: A Prospective Pilot Study. Journal of Clinical Medicine 11:14, pages 4172.
Crossref
Crossref
Yulia Y. Orlova, Sandhya Mehla & Abigail L. Chua. (2022) Drug Safety in Episodic Migraine Management in Adults Part 1: Acute Treatments. Current Pain and Headache Reports 26:7, pages 481-492.
Crossref
Crossref
Miral Patel, Nithun Saha, Shruti Patel, Priyanka Ahlawat, Abhay Dharamsi & Asha Patel. (2022) Development of Bromfenac Sodium Loaded Pluronic Nanomicelles:
Characterization and Corneal Permeation Study. Recent Advances in Drug Delivery and Formulation 16:1, pages 68-78.
Crossref
Crossref
Deanna H. Dang, Kamran M. Riaz & Dimitrios Karamichos. (2022) Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets. Drugs 82:2, pages 145-167.
Crossref
Crossref
E. N. Matyukhina. (2021) The Use of Bromfenac Ophthalmic Solution in Clinical Practice (Literature Review). Ophthalmology in Russia 18:4, pages 784-790.
Crossref
Crossref
Chen Chen, Chenguang Wang, Xuebin Zhou, Lingxian Xu, Han Chen, Kun Qian, Bo Jia, Guanfang Su & Jinling Fu. (2021) Nonsteroidal anti-inflammatory drugs for retinal neurodegenerative diseases. Prostaglandins & Other Lipid Mediators 156, pages 106578.
Crossref
Crossref
Olaf Dammann, José Carlos Rivera & Sylvain Chemtob. (2021) The prenatal phase of retinopathy of prematurity. Acta Paediatrica 110:9, pages 2521-2528.
Crossref
Crossref
Jordan K. RobertsJessica M. MeekinsJames K. RoushAmy J. Rankin. (2021) Effects of topical instillation of 0.1% diclofenac sodium, 0.5% ketorolac tromethamine, and 0.03% flurbiprofen sodium on corneal sensitivity in ophthalmologically normal cats. American Journal of Veterinary Research 82:1, pages 81-87.
Crossref
Crossref
Satyajit Beura & Prabhakar Chetti. (2020) Identification of potential human COX-2 inhibitors using computational modeling and molecular dynamics simulations. Journal of Molecular Structure 1216, pages 128271.
Crossref
Crossref
Idaira Sánchez-Santos, Gustavo A. García-Sánchez, Roberto Gonzalez-Salinas, Mónica Anayatzin Linares-Alba, Abelardo A. Rodríguez-Reyes, Rodrigo García-Santisteban, Vanessa Tirado-González, Elsa Hernández-Piñamora, Daniel García-Arzate, Virgilio Morales-Cantón & Hugo Quiroz-Mercado. (2020) Intravitreal bromfenac liposomal suspension (100 μg / 0.1 ml). A safety study in rabbit eyes. Experimental Eye Research 194, pages 108020.
Crossref
Crossref
CheSuraya Zin, NorzainiRos Nozid, AmaliaAthirah Razak, SitiNuraisyah Hashim, NurAimi Mazlan, Norhayati Daud & SitiHalimah Bux. (2020) Research on nonsteroidal anti-inflammatory drugs in Malaysia: A bibliometric analysis. Journal of Pharmacy And Bioallied Sciences 12:6, pages 707.
Crossref
Crossref
Seok Hyeon SongSeung Kook BaekMin Woo LeeYoung Hoon Lee. (2020) Effect of 0.1% Bromfenac for Preventing Macular Edema after Cataract Surgery in Patients with Diabetes. Korean Journal of Ophthalmology 34:1, pages 46.
Crossref
Crossref
Vrinda Sharma, Parth Bhatia, Ozair Alam, Mohd. Javed Naim, Farah Nawaz, Aadil Ahmad Sheikh & Mukund Jha. (2019) Recent advancement in the discovery and development of COX-2 inhibitors: Insight into biological activities and SAR studies (2008–2019). Bioorganic Chemistry 89, pages 103007.
Crossref
Crossref
Shahenda A El Gharbawy, Essam A Darwish, Khaled G Abu Eleinen & Moataz Hamed Osman. (2018) Efficacy of addition of nepafenac 0.1% to steroid eye drops in prevention of post-phaco macular edema in high-risk eyes. European Journal of Ophthalmology 29:4, pages 453-457.
Crossref
Crossref
Dipak Panigrahy, Allison Gartung, Jun Yang, Haixia Yang, Molly M. Gilligan, Megan L. Sulciner, Swati S. Bhasin, Diane R. Bielenberg, Jaimie Chang, Birgitta A. Schmidt, Julia Piwowarski, Anna Fishbein, Dulce Soler-Ferran, Matthew A. Sparks, Steven J. Staffa, Vidula Sukhatme, Bruce D. Hammock, Mark W. Kieran, Sui Huang, Manoj Bhasin, Charles N. Serhan & Vikas P. Sukhatme. (2019) Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. Journal of Clinical Investigation 129:7, pages 2964-2979.
Crossref
Crossref
Horace Massa, Panagiotis Georgoudis & Georgios D Panos. (2019)
Dexamethasone intravitreal implant (OZURDEX
®
) for macular edema secondary to noninfectious uveitis: a review of the literature
. Therapeutic Delivery 10:6, pages 343-351.
Crossref
Crossref
Melissa M. Toyos. (2019) Comparison of Once-Daily Bromfenac 0.07% Versus Once-Daily Nepafenac 0.3% in Patients Undergoing Phacoemulsification. Ophthalmology and Therapy 8:2, pages 261-270.
Crossref
Crossref
Parteek Prasher, Harish Mudila, Mousmee Sharma & Beena Khati. (2019) Developmental perspectives of the drugs targeting enzyme-instigated inflammation: a mini review. Medicinal Chemistry Research 28:4, pages 417-449.
Crossref
Crossref
John Hovanesian & Edward Holland. (2019) Tolerability and toxicity of topically applied nepafenac 0.3% compared with generic ketorolac 0.5%. Journal of Cataract and Refractive Surgery 45:2, pages 174-180.
Crossref
Crossref
Sedigheh Fekri Aval, Nosratollah Zarghami, Effat Alizadeh & Seyed Abolghasem Mohammadi. (2018) The effect of ketorolac and triamcinolone acetonide on adipogenic and hepatogenic differentiation through miRNAs 16/15/195: Possible clinical application in regenerative medicine. Biomedicine & Pharmacotherapy 97, pages 675-683.
Crossref
Crossref
William Trattler & Kamran Hosseini. (2017) Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study. Ophthalmology and Therapy 6:2, pages 277-284.
Crossref
Crossref
Songshan Li, Andina Hu, Wei Wang, Xiaoyan Ding & Lin Lu. (2017) Combinatorial treatment with topical NSAIDs and anti-VEGF for age-related macular degeneration, a meta-analysis. PLOS ONE 12:10, pages e0184998.
Crossref
Crossref
Linlin Zhang, Ruichen Shu, Qi Zhao, Yize Li, Chunyan Wang, Haiyun Wang, Yonghao Yu & Guolin Wang. (2017) Preoperative But Not Postoperative Flurbiprofen Axetil Alleviates Remifentanil-induced Hyperalgesia After Laparoscopic Gynecological Surgery. The Clinical Journal of Pain 33:5, pages 435-442.
Crossref
Crossref
Alejandro Rodríguez-García, Julio C. Hernández-Camarena, Gilberto R. López-Jaime & José A. Nava-García. (2017) Effect of Topical Nonsteroidal Anti-inflammatory Drugs on Pupillary Size During Uncomplicated Cataract Surgery. Journal of Refractive Surgery 33:4, pages 236-242.
Crossref
Crossref
Jennifer Lu, Robert English, Brad Nadelstein, Anne Weigt, Andrew Berdoulay, Dan Binder & Esther Ngan. (2016) Comparison of topically applied flurbiprofen or bromfenac ophthalmic solution on post‐operative ocular hypertension in canine patients following cataract surgery. Veterinary Ophthalmology 20:2, pages 107-113.
Crossref
Crossref
José Carlos Rivera, Rabah Dabouz, Baraa Noueihed, Samy Omri, Houda Tahiri & Sylvain Chemtob. (2017) Ischemic Retinopathies: Oxidative Stress and Inflammation. Oxidative Medicine and Cellular Longevity 2017, pages 1-16.
Crossref
Crossref
L. David Waterbury. (2017) An Alternative to Topical Dosing to Deliver Drugs to Target Tissues. Journal of Ocular Pharmacology and Therapeutics 33:1, pages 3-4.
Crossref
Crossref
Richard S. Hoffman, Rosa Braga-Mele, Kendall Donaldson, Geoffrey Emerick, Bonnie Henderson, Malik Kahook, Nick Mamalis, Kevin M. Miller, Tony Realini, Neal H. Shorstein, Richard K. Stiverson & Barbara Wirostko. (2016) Cataract surgery and nonsteroidal antiinflammatory drugs. Journal of Cataract and Refractive Surgery 42:9, pages 1368-1379.
Crossref
Crossref
Tae Hee Lee, Won Choi, Yong Sok Ji & Kyung Chul Yoon. (2015) Comparison of ketorolac 0.45% versus diclofenac 0.1% for macular thickness and volume after uncomplicated cataract surgery. Acta Ophthalmologica 94:3.
Crossref
Crossref
Raquel Goldhardt & Bradley Simon Rosen. (2016) Uveitic Macular Edema: Treatment Update. Current Ophthalmology Reports 4:1, pages 30-37.
Crossref
Crossref
Shouvik Saha & Elizabeth M. Graham. 2016. Intraocular Inflammation. Intraocular Inflammation
285
292
.
Sergey Yurievich Astakhov & Medeya Vakhtangovna Gobedzhishvili. (2015) Non-steroidal anti-inflammatory drugs in the post-operative treatment of ophthalmic patients. Ophthalmology Reports 8:3, pages 45-48.
Crossref
Crossref
M-Z Zhai, H-H Wu, J-J Li, L-P Jiang, Z-S Gao, W Hu, Y Liu & Y-T Wang. (2015) Topical bromfenac for post-cataract extraction: A systematic review and pooled analysis. European Journal of Inflammation 13:2, pages 130-135.
Crossref
Crossref
Ji Won JungByung Hoon ChungEung Kweon KimKyoung Yul SeoTae-im Kim. (2015) The Effects of Two Non-Steroidal Anti-Inflammatory Drugs, Bromfenac 0.1% and Ketorolac 0.45%, on Cataract Surgery. Yonsei Medical Journal 56:6, pages 1671.
Crossref
Crossref
Geraldine R. Slean & Rahul N. Khurana. (2015) Local Therapeutic Options for Uveitic Cystoid Macular Edema. International Ophthalmology Clinics 55:3, pages 39-61.
Crossref
Crossref
Hiroshi Fujishima, Miki Fuseya, Masarou Ogata & Dogru Murat. (2015) Efficacy of Bromfenac Sodium Ophthalmic Solution for Treatment of Dry Eye Disease. Asia-Pacific Journal of Ophthalmology 4:1, pages 9-13.
Crossref
Crossref
R. B. Raffa, J. A. Gudin, S. Nalamachu & J. V. PergolizziJrJr. (2014) ‘Selective’ COX-1 or COX-2 NSAIDs: time to change a misleading measure. Journal of Clinical Pharmacy and Therapeutics 39:5, pages 455-456.
Crossref
Crossref
Tetsuo Kida, Seiko Kozai, Hiroaki Takahashi, Mitsuyoshi Isaka, Hideki Tokushige & Taiji Sakamoto. (2014) Pharmacokinetics and Efficacy of Topically Applied Nonsteroidal Anti-Inflammatory Drugs in Retinochoroidal Tissues in Rabbits. PLoS ONE 9:5, pages e96481.
Crossref
Crossref
Afshin ShafieeLyle M. BowmanEddie HouKamran Hosseini. (2013) Aqueous Humor Penetration of Ketorolac Formulated in DuraSite or DuraSite 2 Delivery Systems Compared to Acular LS in Rabbits. Journal of Ocular Pharmacology and Therapeutics 29:9, pages 812-816.
Crossref
Crossref
Qi-wei Wang, Ke Yao, Wen Xu, Pei-qing Chen, Xing-chao Shentu, Xin Xie, Yan Weng, Li Zhang, Chong-fei Jin, Wei Wu, Ya-nan Zhu & Yin-hui Yu. (2013) Bromfenac Sodium 0.1%, Fluorometholone 0.1% and Dexamethasone 0.1% for Control of Ocular Inflammation and Prevention of Cystoid Macular Edema after Phacoemulsification. Ophthalmologica 229:4, pages 187-194.
Crossref
Crossref
Andrea Russo, Ciro Costagliola, Luisa Delcassi, Francesco Parmeggiani, Mario R. Romano, Roberto dell'Omo & Francesco Semeraro. (2013) Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema. Mediators of Inflammation 2013, pages 1-11.
Crossref
Crossref
Scott D. Schoenberger & Stephen J. Kim. (2013) Nonsteroidal Anti-Inflammatory Drugs for Retinal Disease. International Journal of Inflammation 2013, pages 1-8.
Crossref
Crossref
MeiZi Wang, Wu Liu, QingJun Lu, HuiYang Zeng, SuMeng Liu, YanKun Yue, HaiTing Cheng, Ying Liu & Ming Xue. (2012) PHARMACOKINETIC COMPARISON OF KETOROLAC AFTER INTRACAMERAL, INTRAVITREAL, AND SUPRACHOROIDAL ADMINISTRATION IN RABBITS. Retina 32:10, pages 2158-2164.
Crossref
Crossref
Hua Yu, Jianxin Chen, Xue Xu, Yan Li, Huihui Zhao, Yupeng Fang, Xiuxiu Li, Wei Zhou, Wei Wang & Yonghua Wang. (2012) A Systematic Prediction of Multiple Drug-Target Interactions from Chemical, Genomic, and Pharmacological Data. PLoS ONE 7:5, pages e37608.
Crossref
Crossref
Aldino Viegas, João Manso, Marta C. Corvo, M. Manuel B. Marques & Eurico J. Cabrita. (2011) Binding of Ibuprofen, Ketorolac, and Diclofenac to COX-1 and COX-2 Studied by Saturation Transfer Difference NMR. Journal of Medicinal Chemistry 54:24, pages 8555-8562.
Crossref
Crossref
Harald Lenz, Johan Raeder, Tomas Draegni, Fridtjof Heyerdahl, Martin Schmelz & Audun Stubhaug. (2011) Effects of COX inhibition on experimental pain and hyperalgesia during and after remifentanil infusion in humans. Pain 152:6, pages 1289-1297.
Crossref
Crossref
L. David WaterburyDanielle GalindoLinda VillanuevaCathy NguyenMilan PatelLisa BorbridgeMayssa AttarRhett M. SchiffmanDavid A. Hollander. (2011) Ocular Penetration and Anti-inflammatory Activity of Ketorolac 0.45% and Bromfenac 0.09% Against Lipopolysaccharide-Induced Inflammation. Journal of Ocular Pharmacology and Therapeutics 27:2, pages 173-178.
Crossref
Crossref
Eric D. Donnenfeld, Louis D. Nichamin, David R. Hardten, Michael B. Raizman, William Trattler, Rajesh K. Rajpal, Louis M. Alpern, Carlos Felix, Ronald R. Bradford, Linda Villanueva, David A. Hollander & Rhett M. Schiffman. (2011) Twice-Daily, Preservative-Free Ketorolac 0.45% for Treatment of Inflammation and Pain After Cataract Surgery. American Journal of Ophthalmology 151:3, pages 420-426.e1.
Crossref
Crossref
Barry A. Schechter & William Trattler. (2010) Efficacy and safety of bromfenac for the treatment of corneal ulcer pain. Advances in Therapy 27:10, pages 756-761.
Crossref
Crossref
Yoshikazu Shimomura, Shiro Higaki & Keizo Watanabe. (2010) Suppression of herpes simplex virus 1 reactivation in a mouse eye model by cyclooxygenase inhibitor, heat shock protein inhibitor, and adenosine monophosphate. Japanese Journal of Ophthalmology 54:3, pages 187-190.
Crossref
Crossref
Stephen J. Kim, Allan J. Flach & Lee M. Jampol. (2010) Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. Survey of Ophthalmology 55:2, pages 108-133.
Crossref
Crossref
Johnny Gayton. (2009) Concentration and dosing of ketorolac versus bromfenac. Journal of Cataract and Refractive Surgery 35:7, pages 1319.
Crossref
Crossref
Frank A. Bucci & David L. Waterbury. (2009) Reply : Concentration and dosing of ketorolac versus bromfenac. Journal of Cataract and Refractive Surgery 35:7, pages 1320.
Crossref
Crossref
Kensaku MiyakeTakahiro OgawaTetsuya TajikaJames A. GowTimothy R. McNamara. (2008) Ocular Pharmacokinetics of a Single Dose of Bromfenac Sodium Ophthalmic Solution 0.1% in Human Aqueous Humor. Journal of Ocular Pharmacology and Therapeutics 24:6, pages 573-578.
Crossref
Crossref
Frank A. Bucci & David L. Waterbury. (2008) Comparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: Aqueous drug absorption and prostaglandin E2 levels. Journal of Cataract and Refractive Surgery 34:9, pages 1509-1512.
Crossref
Crossref
George A. BaklayanHal M. PattersonClara K. SongJames A. GowTimothy R. McNamara. (2008)
24-Hour Evaluation of the Ocular Distribution of
14
C-Labeled Bromfenac Following Topical Instillation into the Eyes of New Zealand White Rabbits
. Journal of Ocular Pharmacology and Therapeutics 24:4, pages 392-398.
Crossref
Crossref
Amany EL-Shazly, Amal EL-Gohary, Laila EL-Shazly & Ghada EL-Hossary. (2008) Comparison between two cyclooxygenase inhibitors in an experimental dry eye model in albino rabbits. Acta Pharmaceutica 58:2, pages 163-173.
Crossref
Crossref
Munish Ahuja, Avinash S. Dhake, Surendra K. Sharma & Dipak K. Majumdar. (2008) Topical Ocular Delivery of NSAIDs. The AAPS Journal 10:2.
Crossref
Crossref
Hon-Vu Q. Duong, Kenneth C. Westfield & Thomas H.F. Chalkley. (2007) Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery. Journal of Cataract and Refractive Surgery 33:11, pages 1925-1929.
Crossref
Crossref
Eric D. Donnenfeld, Edward J. Holland, Robert H. Stewart, James A. Gow & Lisa R. Grillone. (2007) Bromfenac Ophthalmic Solution 0.09% (Xibrom) for Postoperative Ocular Pain and Inflammation. Ophthalmology 114:9, pages 1653-1662.e1.
Crossref
Crossref
Tom Walters, Michael Raizman, Paul Ernest, Johnny Gayton & Robert Lehmann. (2007) In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. Journal of Cataract and Refractive Surgery 33:9, pages 1539-1545.
Crossref
Crossref
Eric D. Donnenfeld & Ashley Donnenfeld. (2006) Global Experience With Xibrom (Bromfenac Ophthalmic Solution) 0.09%: The First Twice-daily Ophthalmic Nonsteroidal Anti-inflammatory Drug. International Ophthalmology Clinics 46:4, pages 21-40.
Crossref
Crossref